Search NLS News

Sometimes a simple event can have far-reaching consequences, as in the case of Princeton University professor Dr. David MacMillan, when a leaky roof led to an award-filled career in chemistry. The MacMillan family lived in the small town of Bellshill, Scotland, and David MacMillan’s older brother was the first in the neighborhood to go to […]

One of the best things with being a scientist, according to Nobel Laureate Benjamin List, is that you discover things that nobody else has seen before – and, following his own advice, he is now happy trying to tackle “holy grails” in catalysis. “As chemists, we can create things that are new to the universe […]

The Nobel Prize in Chemistry 2021 shed light on a simple, sustainable and smart molecular building tool that has had a great impact on pharmaceutical production. The Royal Swedish Academy of Sciences decided to award the Nobel Prize in Chemistry 2021 to Benjamin List and David MacMillan, for “the development of asymmetric organocatalysis.” Their discoveries […]

The Novo Nordisk Foundation (NNF) has awarded a 195  million DKK grant for establishing a national, brickless Danish Diabetes and Endocrine Academy (DDEA) with an executive office based at Odense University Hospital. The purpose of the Academy is to develop and strengthen the quality of Danish diabetes and endocrine research and research-based education. The Academy […]

SynAct Pharma has announced that its share started trading on Nasdaq Stockholm’s main list July 12, 2022. “SynAct Pharma has worked hard with its pipeline to make it to where it is today. To be traded on the main market is an important landmark and a stamp of quality for SynAct, which enables us to […]

The Board of Directors of BioInvent International has resolved to issue 6,496,788 new shares in a directed share issue to international and Swedish institutional investors based on the authorization granted by the Annual General Meeting on April 28, 2022. “The performed directed share issue provides us with an even stronger base of institutional investors and […]

Orion Corporation and MSD have announced a global development and commercialisation agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic […]

We would like to thank our readers, subscribers and collaboration partners for a fruitful and eventful Q1 + Q2 2022, and we wish you all a most wonderful summer! The next NLS Newsletter will be sent out on August 11, but our news feed and social media channels will continue to provide you with the […]

There are so many benefits for patients and society, but also for the healthcare itself, from performing clinical trials. So why are the sponsor initiated trials so hard to bring about? And how come that lack of resources is the most common reason for not performing clinical trials, when the clinic is more than well […]

Cyxone has received a response from a Type B pre-IND meeting with the US Food and Drug Administration (FDA) regarding the upcoming study with the drug candidate Rabeximod, which is in development as a treatment for rheumatoid arthritis (RA). “We are pleased to now have received a written response from the pre-IND interaction we have […]